A novel and safe approach for treating cognitive disorders

Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (neurosteroids). The company's primary focus is on the development and commercialization of novel therapeutics to treat CNS related disorders in patients with liver disease, such as Hepatic Encephalopathy (HE) in patients with liver cirrhosis.

 

Liver disease and its complications account for a growing and substantial disease burden worldwide. Hepatic Encephalopathy is a syndrome of episodically impaired brain function which remains the most common reason for readmission of patients hospitalized with decompensated cirrhosis. Symptoms of HE range from impaired cognitive function (covert HE) to clinically evident impairment (overt HE) manifested by a spectrum of abnormalities ranging from confusion to depressed consciousness and coma. Impaired cognitive function is associated with an increased risk of overt HE and there are today no treatments available that directly target the brain abnormalities believed to responsible for HE.

 

The company's therapy represents a new target class. The lead compound, golexanolone (GR3027), in clinical development for HE, is a GABAA receptor modulating steroid antagonist (GAMSA) designed to antagonize GABAA receptor activation and neuroinhibition by endogenous neuroactive steroids. Golexanolone has been shown to restore different types of neurological impairments including cognitive and sleep alternations in experimental models. The drug candidate enters the CNS and reverses the inhibitory effects of the neurosteroid allopregnanolone on brain function in humans. Collectively, these findings strongly implicate that golexanolone is a promising novel treatment for a wide range of cognitive disorders.

News

 

2020-09-02

Umecrine Cognition to present clinical Phase 2a results as "Poster of Distinction" at AASLD International Liver Meeting, November

13-16, 2020

 

Brain.jpg
Banner.jpg

CONTACT

 

Magnus Doverskog

Chief Executive Officer

Phone +46 8 524 844 84

magnus.doverskog@umecrine.se

 

More contact details

VISITING ADDRESS

 

Karolinska Institutet Science Park

Fogdevreten 2

SE - 171 65 Solna

Sweden

 

See on map

COMPANY INFORMATION

 

Umecrine Cognition AB

Registred office in Umeå

Reg no 556698-3655

 

 

© 2015 Umecrine